Sanjeev Rajakulendran
Overview
Explore the profile of Sanjeev Rajakulendran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Balaratnam M, Rugg-Gunn F, Okin R, Powell F, Prior S, Petrochilos P, et al.
Clin Med (Lond)
. 2024 Aug;
24(6):100234.
PMID: 39173716
Integrated care systems join up health and care services, so that people have the support they need, in the right place, at the right time. The aims include improving outcomes...
2.
Allard J, Henley W, Sellers A, OShaughnessy E, Thomson O, McLean B, et al.
Epilepsy Behav
. 2024 Jun;
158:109906.
PMID: 38936308
Introduction: In England, nearly a quarter of people with intellectual disability (PwID) have epilepsy. Though 70 % of PwID have pharmaco-resistant seizures only 10 % are prescribed anti-seizure medication (ASMs)...
3.
Allard J, Sellers A, Henley W, McLean B, Parrett M, Rajakulendran S, et al.
Seizure
. 2024 Jun;
120:25-32.
PMID: 38897161
Introduction: People with Intellectual Disabilities (PwID) are twenty times more likely than general population to have epilepsy. Guidance for prescribing antiseizure medication (ASM) to PwID is driven by trials excluding...
4.
Jindal M, Neligan A, Rajakulendran S
Seizure
. 2023 Aug;
111:98-102.
PMID: 37556986
Objective: We investigated the management and outcome of early and established status epilepticus including timing, dosing and selection of benzodiazepines along with the timing and efficacy of second line treatments....
5.
Tharmaraja T, Ho J, Neligan A, Rajakulendran S
Epilepsia
. 2023 Feb;
64(5):1113-1124.
PMID: 36727541
New-onset refractory status epilepticus (NORSE) is a devastating neurological presentation. There is a paucity of large studies on NORSE as it is a relatively new clinical syndrome. The aim of...
6.
Neligan A, Rajakulendran S
Epilepsy Behav
. 2022 Dec;
138:109050.
PMID: 36549100
Earlier and more aggressive treatment of status epilepticus has long been established orthodoxy. In addition to increasing therapeutic options, it is of critical importance to understand whether or not this...
7.
Green S, Hare N, Kassam M, Rugg-Gunn F, Koepp M, Sander J, et al.
Epilepsy Behav
. 2022 Aug;
135:108868.
PMID: 35985166
Introduction: Brivaracetam (BRV) is licensed as an adjunctive treatment for focal epilepsy. We describe our clinical experience with BRV at a large UK tertiary center. Methods: Adults initiated on BRV...
8.
Nakajima M, Pauls M, Rajakulendran S
J Clin Neurol
. 2022 Jan;
18(1):105-107.
PMID: 35021286
No abstract available.
9.
Neligan A, Kerin B, Walker M, Rajakulendran S
Epilepsy Behav
. 2021 Nov;
125:108387.
PMID: 34781063
The introduction and widespread adoption of the term 'NORSE' - new-onset refractory status epilepticus - raises both fundamental conceptual and pragmatic questions. We studied a cohort of patients with 'NORSE'...
10.
Neligan A, Walker M, Rajakulendran S
Pract Neurol
. 2021 Oct;
22(2):94-95.
PMID: 34611050
No abstract available.